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RESEARCH PAPER
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ABSTRACT
MiR-455 has been verified a key regulator of brown adipose tissue and adipose tissue-specific over-
expression of miR-455 (ap2-miR-455) mice could combat high-fat-diet-induced obesity. This study is to
verify overexpression of miR-455 could ameliorate the lipid accumulation andmetabolism in the liver of
db/db diabeticmice and explore the potentialmechanisms. Diabeticmice (db/db) and controlmice (db/
m) were randomly divided into four groups. After overexpression of miR-455 in the liver of db/db mice,
the triglycerides level in both serum and liver decreased, the lipid deposit in liver was improved, the
expression of fatty acid synthase, stearoyl-CoA desaturase 1, sterol regulatory element binding protein
1c (SREBP-1c) and acetyl-CoA carboxylase (ACCα) was also significantly down-regulated. TargetScan
indicated that suppressor of cytokine signalling 3 (SOCS3) is predicated to target miR-455 and the
protein of SOCS3 in the liver of db/db mice after intervention was significantly decreased. The dual
luciferase reporter assay showed that SOCS3 was target gene of miR-455. In vitro, in Palmitate (PA)-
stimulated human normal liver (LO2) cells, transfected miR-455 mimic could significantly inhibit the
expression of SOCS3, while transfected miR-455 inhibitor could up-regulate the expression of SOCS3.
Transfecting LO2 cells with siRNA of SOCS3 could significantly down-regulate the protein expression of
SREBP-1c and ACCα. Our study showed that overexpression of miR-455 in the liver could improve lipid
metabolism in diabetic mice by down-regulating its target gene SOCS3.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is closely related
to diabetes. The estimated global prevalence of NAFLD is
25%, which is as high as 30% in some countries [1]. Recent
clinical researches have revealed that diabetes plays an
important role in the progression of NAFLD [2,3] and
has become a strong predictor of non-alcoholic steatohe-
patitis (NASH) and liver fibrosis [4]. However, there is still
a lack of effective treatment for NAFLD [5].
MicroRNA (miRNA) is a non-coding single-stranded
RNA molecule of approximately 20–24 nucleotides in
length, regulates gene expression at the post-
transcriptional level by binding to the mRNA of the target
gene [6]. MiRNA can regulate a variety of biological pro-
cesses such as developmental processes, tumorigenesis and
cell proliferation and apoptosis, not only participates in the
process of multiple diseases, but also serves as a marker
molecule for diagnosing diseases [7]. MiRNAs have been
used as the clinical diagnostic markers for NAFLD/NASH,
and even the potential predictors of primary liver cancer
[8]. Our previous study shows that miR-455 is a key reg-
ulator of brown adipose tissue that promotes differentia-
tion of brown adipocytes by targetingNecdin, Runx1t1 and
HIF1an [9]. Recent studies indicate that miR-455 could
improve the progression of different cancers [10,11], while
there is still lack of the research focused on the regulation of
miR-455 on liver metabolism.
In this study, we observed the changes in liver lipid
metabolism in diabetic mice (db/db) after the overexpres-
sion of miR-455 in the liver. Furthermore, we found that
miR-455 could improve the liver metabolism by inhibiting
suppressor of cytokine signalling 3 (SOCS3), as a member
of SOCS family, negatively regulates the transduction of
cytokine signalling [12]. At the same time, SOCS3 also
plays an important role in the regulation of metabolism.
The overexpression of miR-19a [13] and miR-125a [14]
could improve themetabolism of glucose and lipid through
targeting SOCS3. We found that miR-455 ameliorated the
lipid metabolic disorder of liver in db/db mice and this
improvement may be caused by inhibition of SOCS3.
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Methods
Animal experiments
All animal experiments were approved by the Animal
Care and Use Committee of the Southern Medical
University. 20 male C57BLKS/J diabetic mice (db/db;
6 weeks) and 20 male C57BLKS/J normal mice (db/m;
6 weeks) were purchased from the Nanjing Model
Animal Centre. Mice were raised in the specific patho-
gen free barrier facility at the Southern Medical
University under the controlled environment (tempera-
ture 22°C; 12 hours light/dark cycle). All mice were fed
a standard chow diet (Guangzhou, China) and water.
After 1 week of adaptive culture, the mice were
randomly divided into four groups: db/db-455 mice
(n = 10), db/db-con mice (n = 10), db/m-455 mice
(n = 10) and db/m-con mice (n = 10). The db/db-455
and db/m-455 mice were injected via tail vein with a
plasmid construct expressing miR-455 (pCMV-miR-
455)-miR-455 (Obio Technology, Shanghai) diluted
with phosphate buffered saline and the db/db-con and
db/m-con mice were given a pCMV (Obio Technology,
Shanghai) injection. All mice received weekly injection
for 4 weeks. When the experiment was over, the blood
and liver tissue were collected after the mice were
anesthetize by 1% pentobarbitol sodium.
Metabolic measurement
The body weight (BW) and the random blood glucose
(RBG) were recorded every 2 weeks. The serum and
liver triglyceride (TG) content were detected by the
Triglyceride detection kit (Jiancheng, Nanjing).
Cell culture and transfection
Human normal liver cell line (LO2) and human
embryonic kidney 293 cell line (HEK293) were
obtained from the Cell Bank of the Chinese Academy
of Sciences (Shanghai, China). All cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) medium
(Gibco, USA) supplemented with 10% foetal bovine
serum (FBS) (Gibco, USA) and 1% penicillin-
streptomycin in a 5% CO2 atmosphere at 37°C.
Palmitate (PA) (Sigma, USA) was used to mimic the
hyperlipidaemia in cells. After stimulated with PA for
24 hours, the cells were transfected with miR-455
mimics, miR-455 inhibitors, small interfering
RNAs (siRNAs) and negative control (RiboBio,
Guangzhou) respectively for 48 hours, and the transfec-
tion was performed by Lipofectamine 3000 reagent
(Invitrogen, MA).
Bioinformatics prediction and dual luciferase
reporter assay
TargetScan (http://www.targetscan.org/) was used to pre-
dict the potential targets of miR-455, the target site of miR-
455-5p in SOCS3 3′-UTR was shown in Figure 4(g).
Luciferase reporter plasmid wide-type (wt) or mutated-
type (mut) were co-transfected into the 293 T cells with
miR-455 mimics, respectively. The luciferase activity of the
cells was measured by Luciferase Reporter Assay System
(Promega Corporation) after 48 hours of transfection.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from the cells and liver tissue by
Trizol (Invitrogen, MA) and cDNA was synthesized by
PrimeScript RT Master Mix (Takara, Japan). The cDNA
ofmiR-455 andU6was synthesized byMiRNAcDNAFirst
Strand Synthesis Kit (TianGen, China). The qRT-PCR was
performed with SYBR Green real-time Kit (Takara, Japan)
and qRT-PCR of miR-455 and U6 was performed with
SYBR Green real-time Kit (TianGen, China) on Roche
LightCycler 480 Real-Time PCR System. β-actinwas served
as housekeeping gene inmouse liver andLO2 cells.U6were
used as housekeeping gene in compared with miR-455.
Collect CT values of genes, and then use the 2-ΔΔCt
method to analyse the expression of all genes. All primers
were listed in Tables 1 & 2.
Western blot analysis
The protein of cells and liver tissue was extracted by
RIPA lysis buffer (KeyGen, China) and the concentration
of protein was quantified by BCA Protein Assay Kit
(Takara, Japan). The denatured protein (20 ug) was
separated by 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis and transferred onto
the polyvinylidene difluoride membrane. After being
blocked with 5% skim milk for 1 hour at ambient tem-
perature, the membrane was incubated with primary
antibodies of sterol regulatory element binding protein
1c (SREBP-1c) (1:1000, Abclone, China), acetyl-CoA
carboxylase (ACCα) (1:1000, Abclone, China), fatty acid
synthase (FAS) (1:1000, Abclone, China), NADPH (nico-
tinamide adenine dinucleotide phosphateoxidase) oxi-
dase 4 (NOX4) (1:1000, Abclone, China), SOCS3
(1:1000, Abclone, China), IL-6 (1:1000, CST, USA) and
β-actin (1:1000, Zhongshan, China) at 4°C overnight.
Then the membrane was incubated with horseradish
peroxidase labelled secondary antibody (1:5000) for
1 hour after being washed three times with TBST (tris-
buffered saline Tween-20). Enhanced chemilumines-
cence reagent (Millipore, USA) was used to detect
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immunoreactive bands and the Image J software was
used to analyse the bands.
Histological staining
The liver tissue was first fixed with 4% paraformaldehyde,
then dehydrated and embedded in paraffin. The tissue
embedded in the paraffin was subjected to H&E staining,
and the freshly fixed tissue was stained with oil red
O. Olympus B × 20 upright light microscope (Olympus,
Tokyo, Japan) was used to detect all sections.
Statistical Analysis
Data were expressed as the mean ± SD. Two-tailed
Student’s t test was used to compare two independent
groups, and one-way ANOVA was used to examine the
differences among four independent groups. Statistical
analysis was performed by using SPSS 20.0. P < 0.05
was considered statistically significant.
Results
The changes of basal metabolic indicator in mice
after the intervention of miR-455
Db/db mice showed obvious obesity after 6 weeks and
polydipsia, polyphagia and polyuria. The weight (Figure 1
(a)) and RBG (Figure 1(b)) of db/db mice were also
significantly higher than those of db/m mice, indicating
the establishment of diabetesmodel. After intervention, the
expression of miR-455 was significantly increased in the
liver of db/db-455 mice and db/m-455 mice compared to
db/db-con mice and db/m-con mice respectively (Figure 1
(c)). During the whole experiment, the BW (Figure 1(d))
and RBG (Figure 1(e)) of db/db-con and db/db-455 mice
were higher than those of db/m mice. Although there was
no obvious improvement in the levels of BW and blood
glucose in db/db-455 mice, the overexpression of miR-455
in liver significantly reduced serum TG levels (Figure 1(f))
and liver TG content (Figure 1(g)) compared with db/db-
con mice.
Overexpression of miR-455 improved the liver lipid
metabolism
Compared with db/m-con mice, the mRNA expression of
peroxisome proliferator-activated receptor γ (PPARγ),
FAS, fatty acid transporter (CD36) and stearoyl-CoA desa-
turase 1 (SCD-1) was notable up-regulated in db/db-con
mice, the mRNA expression of ACCα and SREBP-1c also
increased although without statistical significant (Figure 2
(a)). However, themRNA expression levels of FAS, SCD-1,
SREBP-1c and ACCα in db/db-455 mice were significantly
lower than those in db/db-con group (Figure 2(a)). In
addition, we detected the protein expression of SREBP-1c,
ACCα and FAS in the liver of db/db-455 and db/db-con
mice, the results were consistent with the expression trend
of mRNA (Figure 3(b)). H&E staining showed liver struc-
tural disorder, vacuolar degeneration of hepatocytes and
inflammatory infiltration in db/db-con mice (Figure 2(d))
compared with db/m-con mice (Figure 2(b)), but the over-
expression ofmiR-455 in liver ameliorated these changes in
db/db-455 mice (Figure 2(e)). Simultaneously, the oil red
O staining revealed that lipid deposition in liver of db/db-
con mice (Figure 2(h)) was severe than db/m-con mice
(Figure 2(f)), while the overexpression of miR-455 signifi-
cantly reduced the number and size of liver lipid droplets in
db/db-455 mice (Figure 2(i)).
Table 2. Primer sequences (human).
Gene Forward prime (5ʹ-3ʹ) Reverse prime (5ʹ-3ʹ)
β-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT
PPARγ GGGATCAGCTCCGTGGATCT TGCACTTTGGTACTCTTGAAGTT
FAS ATGTCAGTCACTTGGGCATTA CATCTGGACCCTCCTACCTCT
ACCα ATGTCTGGCTTGCACCTAGTA CCCCAAAGCGAGTAACAAATTCT
SREBP-
1c
CGGAACCATCTTGGCAACAGT CGCTTCTCAATGGCGTTGT
PPARα CTGGCATTTGTTTCTGTTCTTT CTCCTCGGTGACTTATCCTGT
CPT-1 TCCAGTTGGCTTATCGTGGTG TCCAGAGTCCGATTGATTTTTGC
IL-6 ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG
TNF-α CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
NOX4 CAGATGTTGGGGCTAGGATTG GAGTGTTCGGCACATGGGTA
Table 1. Primer sequences (mouse).
Gene Forward prime (5ʹ-3ʹ) Reverse prime (5ʹ-3ʹ)
β-actin GTCCACCCCGGGGAAGGTGA AGGCCTCAGACCTGGGCCATT
PPARγ ATTCTGGCCCACCAACTTCGG CTGCGGAAACTTCAGGAAATG
FAS GGCCAGTGCTATGCTGAGAT CACTTCTGGAGACATCGCAAAC
CD36 ATGGGCTGTGATCGGAACTG TTTGCCACGTCATCTGGGTTT
SCD-1 CTGGCATTTGTTCCGGTTCT CGGGATTGAATGTTCTTGTCGT
SREBP-1c TGGAAGCCTGATGCTTTATCCCCA GGTTCGGAATGCTATCCAGG
ACCα TATTCGGCTGAAGCTGGTGTAC TTCTTGCGATACACTCTGGTGC
TNF-α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
MCP-1 GTTAACGCCCCACTCACCTG GGGCCGGGGTATGTAACTCA
NOX4 TGCCTGCTCATTTGGCTGT CCGGCACATAGGTAAAAGGATG
RUN6 TGGCCCCTGCGCAAGGATG /
MiR-455-5p TATGTGCCTTTGGACTACATCG /
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Overexpression of miR-455 ameliorated the liver
inflammation and oxidative stress
We then detected the liver mRNA expression of
tumour necrosis factor-α (TNF-α), monocyte chemo-
tactic protein-1 (MCP-1) and NADPH oxidase 4
(NOX4), as the indicators of inflammation, the high
expression of TNF-α and MCP-1 in db/db-con mice
was significantly reduced after miR-455 overexpres
sion in the liver of db/db-455 mice (Figure 3(a)).
Overexpression of miR-455 in liver also tremendously
inhibited the mRNA expression of NOX4 in db/db-455
mice, an indicator of oxidative stress (Figure 3(a)).
Also, the protein expression level of SREBP-1c, ACCα,
FAS and NOX4 was significantly decreased in the liver
of db/db-455 mice compared with db/db-con mice
(Figure 3(b)).
Figure 1. The changes of basic metabolism indicator of mice after intervention by miR-455. The BW (g) (a) and RBG (mmol/L) (b) of
mice before intervention. (C) (c) The expression of miR-455 in liver of mice. The BW (d) and the RBG (e) of mice after intervention.
The serum (f) and liver TG (g) content of mice. n = 6–8 per group.
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Cytokine signal transduction inhibitor 3 (SOCS3)
was the target gene of miR-455 in liver
Since the overexpression of miR-455 could improve the
lipid metabolism, inflammation and oxidative stress of db/
db mice, we predicted its possible target genes using
TargetScan software in order to investigate its underlying
mechanism. We found that SOCS3 may be one of the
target genes of miR-455, and the detail bioinformatic ana-
lysis for the target site of miR-455-5p in SOCS3 3′-UTR
was shown in Figure 4(g). Next, we detected the protein
Figure 2. Overexpression of miR-455 improved the liver lipid metabolism. (a) The mRNA expression of PPARγ, FAS, CD36, SCD-1,
SREBP-1c and ACCα in the liver of mice in four groups. H&E (b–e) and oil red O staining (f–i) of liver in four groups. Db/m-con group
(b + f), db/m-455 group (c + g), db/db-con group (d + h), db/db-455 group (e + i). Magnification ×400. n = 6–8 per group.
**P < 0.01 and ***P < 0.001 vs db/m-con group; #P < 0.05 vs db/db-con group.
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levels of SOCS3 in mice. The result indicated that the
overexpression of miR-455 in liver obviously inhibited
the expression of SOCS3 in db/db-455 mice (Figure 4(a)).
To mimic the hyperlipidaemia in vitro, we incubated
the LO2 cells with PA. Lipid metabolism-related gene
expression levels were significantly higher at 0.4 mM PA
stimulation than 0.2 mM PA (Figure 4(b)), so we choose
a stimulus concentration of 0.4 mM and the oil red
O staining also indicated the 0.4 mM was a suitable con-
centration (Figure 4(c,d)). On the basis of PA stimulation,
cells were transfected with mimic and inhibitor of miR-455
respectively. The expression of miR-455 in LO2 cells
increased significantly after treatment with miR-455
mimic (Figure 4(e)), also the expression of miR-455
decreased after intervention with miR-455 inhibitor
(Figure 4(f)). The protein level of SOCS3 was remarkably
down-regulation after intervention by miR-455 mimic in
LO2 cells (Figure 4(e)). On the contrary, the protein level of
SOCS3 was significantly up-regulated after intervention by
miR-455 inhibitor (Figure 4(f)). Then we constructed the
SOCS3 wt plasmids and mut plasmids, which were co-
transfected into 293 T cells with miR-455 mimic. The
luciferase assay showed that the luciferase activity was
significantly decreased after co-transfection of miR-455
mimic and SOCS3 wt plasmids compared to co-
transfection with miR-455 mimic and SOCS3 mut plas-
mids (Figure 4(g)). These results demonstrated that SOCS3
was a target gene of miR-455 in liver.
The effect of knocking down the expression of
SOCS3 in LO2 cells
In order to investigate whether knocking down SOCS3
could affect the metabolism of LO2 cells, we treated the
LO2 cells with siRNA-SOCS3 on the basis of PA. The
mRNA (Figure 5(a)) and protein (Figure 5(b)) expression
of SOCS3was tremendously down-regulation after siRNA-
SOCS3 intervention. SiRNA intervention significantly
reduced mRNA expression of FAS in cells (Figure 5(c)).
Despite themRNA expression of SREBP-1c, ACCα, TNF-α
and interleukin-6 (IL-6) had a decreasing trend, it had not
reached a significant difference. Nevertheless, siRNA inter-
vention of SOCS3 significantly decreased the protein
expression of SREBP-1c, ACCα and IL-6 (Figure 5(d)).
Discussion
The synthesis of hepatic TGs exceeds the rate of catabolism
could lead to the accumulation of TGs. And excessive
Figure 3. Overexpression of miR-455 ameliorated the liver inflammation and oxidative stress. (a): The mRNA expression of TNF-α,
MCP-1 and NOX4 of liver in four groups. (b) The protein levels of SREBP-1c, ACC, FAS and NOX4 in liver of db/db-con group and db/
db-455 group, the quantitative analysis results of protein levels. n = 6–8 per group. *P < 0.05 and **P < 0.01 vs db/m-con group;
#P < 0.05 and ##P < 0.01 vs db/db-con group.
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accumulation of TGs in hepatocytes contribute to the
occurrence of NAFLD [15]. In our study, we observed
obvious obesity and lipid deposition in liver of db/db
mice consistent with the result of published studies
[16,17]. MicroRNAs play an important role in a variety of
diseases [18–20] including the lipid metabolic disorder
[21,22], because they can regulate a wide range of growth
and development processes [7]. Recent studies indicate that
miR-27a [23], miR-194 [24] and miR-146b [25] can target
different genes to regulate the development of NAFLD.
According to our previous research, miR-455 is the key
regulator of BAT in the process of differentiation [9] and
may have an effect on the regulation of lipid synthesis.
Then, we achieved the overexpression of miR-455 to figure
out whether it could improve the lipid metabolism of liver
in db/db mice. The results showed that the serum and liver
Figure 4. SOCS3 was the target gene of miR-455 in liver. (a) The protein level of SOCS3 in liver in four groups and the quantitative analysis
result (n = 6–8 per group). (b) The mRNA expression of PPARγ, FAS, SREBP-1c, ACCα, PPARα and CPT-1 in LO2 cells. The oil red O staining of
cells stimulated with BSA (bovine serum albumin) (c) and 0.4mM PA (d). (e) The expression of miR-455 and SOCS3 in LO2 cells after treatment
of miR-455 mimic. (f) The expression of miR-455 and SOCS3 in LO2 cells after treatment of miR-455 inhibitor. (g) The binding sites of miR-455
and SOCS3. Luciferase reporter assay of the interaction between miR-455 and SOCS3 (n = 3 per group). *P < 0.05 vs db/m-con group;
###P< 0.001 vs db/db-con group. +P< 0.05 and ++ P< 0.01 vs BSA group. &P< 0.05 and &&&P< 0.001 vs mimic control group. ^P< 0.05 vs
inhibitor control group. *P < 0.05 and ***P < 0.001.
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TG content of db/db-455 mice was significantly decreased.
Histological staining results also suggested that there was
improvement in the structural disorder and lipid deposi-
tion in the liver of db/db-455 mice.
Liver is a central regulator of lipid metabolism in
human [26]. Nowadays, a lot of researches have already
confirmed that plenty of molecules are involved in the
lipid metabolism, including PPARγ, SREBP-1c, FAS and
ACCα [26–28]. As the crucial genes for the development
of NAFLD, these genes were significantly up-regulated in
the liver of db/db mice. There was also a significant
increase in CD36 expression, which involved in fatty acid
transport [29]. However, increased expression of these
genes was conspicuously inhibited after the overexpression
of miR-455 in liver. SREBP-1c has been reported as
a upstream signal to directly regulate ACCα and FAS
[30]. In our study, overexpression of miR-455 suppressed
the protein levels of SREBP-1c, ACCα and FAS. Thus,
miR-455 could ameliorate the lipid deposition in db/db
mice by downregulating SREBP-1c and its downstream
signal pathway.
SOCS3 has been reported involving in the progress of
various diseases such as autoimmune diseases [31], cardi-
ovascular diseases [32], metabolic diseases [33] and
tumours [34], which is responsive to an increase in IL-6
and plays a negative regulatory role in cytokine signalling
[12]. It has been shown that miR-19a-3p can promote cell
proliferation and insulin secretion by targeting SOCS3
[13], overexpression of miR-125a-5p also inhibit the
expression of SOCS3 to improve glycolipid metabolism in
the liver [14]. In our study, miR-455 can significantly
reduce serum and liver TG level without affecting BW
Figure 5. The effect of knocking down the expression of SOCS3 in LO2 cells. The mRNA (a) and protein (b) expression of SOCS3 in
LO2 cells after incubated with PA and siRNA-SOCS3. (c) The mRNA expression of SREBP-1c, ACCα, FAS, IL-6, TNF-α and NOX4 in LO2
cells after incubated with PA and siRNA-SOCS3. (d) The protein expression of SREBP-1c, ACCα and IL-6 in cells after c results.
n = 3 per group. ◆◆P < 0.05 and ◆◆◆◆P < 0.01 vs PA-control group.
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and blood glucose, the probable reason is that the cycle of
the experiment is not long enough to significantly improve
blood glucose. In the end of the animal experiment, we
found that the RBG level of db/db-455 group has been
decreasing, but there was no significant difference com-
pared with db/db-con group. We confirmed that SOCS3
was a target gene of miR-455. And Inhibition of SOCS3
could down-regulate SREBP-1c, ACCα and FAS in LO2
cells incubated with PA. Studies have shown that over-
expression of SOCS3 enhances the promoter activity of
SREBP-1c and then promotes the transcription of
SREBP-1c [35]. Therefore, combined with our in vitro
and in vivo experiments, we considered that overexpres-
sion of miR-455 can regulate lipid synthesis genes such as
SREBP-1c by inhibiting its target gene SOCS3, thereby
improve liver lipid metabolism.
Liver inflammation and oxidative stress are very
important mechanisms of NAFLD [36]. In our study,
we observed a significant increase of TNF-α, MCP-1
and NOX4 in db/db mice, which were significantly
decreased by overexpression of miR-455 in db/db
mice. In vitro, IL-6 was further decreased by transfect-
ing siRNA of SOCS3 in LO2 cells. It has been reported
that SOCS3 could promote the expression of inflam-
matory factors by inhibiting the phosphorylation of
JAK2/STAT3 signalling pathway in adipocytes [37].
In conclude, we found that overexpression of miR-
455 in db/db mice could improve the lipid metabolism,
inflammation and oxidative stress in liver by targeting
SOCS3. MiR-455/SOCS3 pathway may be a potential
target for the treatment of abnormal liver lipid meta-
bolism in type 2 diabetes.
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